 <h1>Congratulations! 🎉 </h1>
    <p style="color:#637381;">All done! You’ve completed another milestone.</p>

To continue, enter your details to log in.

We’ve sent a 6‑digit code to #MAIL_ADDRESS#\nPlease check your inbox or spam folder and enter the code below to continue.

Verification code sent

Thank you for the payment. You can now access {collectionName} by simply clicking the button below.

Yes, you’ve successfully ordered! 🎉

Unlock This Exclusive Course

It seems that your email address is not currently on the authorized access list. Please ensure you are using the email address that was invited, or contact the content owner for assistance.

Verification Required for Access

Reporting Thresholds for Degradation Products

Course Overview

Reporting thresholds (the focus of this module)

Operational Rules and Practical Application

Three operational rules from the guideline body that matter for reporting

Slide 3 — Case Study (90 sec)

10-Point Audit / Inspection-Readiness Checklist

Quiz

Q1. A tablet has a maximum daily dose of 1.6 g. What is the reporting threshold for degradation products?

Q2. For a product with a maximum daily dose > 1 g, a degradant is measured at exactly 0.05%. Must it be reported?

Q3. Your product's reporting threshold is 0.05%, but your HPLC method's quantitation limit is 0.10%. What is the problem?

Q4. A product with a 2.5 g maximum daily dose shows an unknown degradant at 0.07%. What is the correct action?

Q5. When calculating total degradation products, which results are summed?

Survey/Feedback

Course Evaluation Survey

Practical Application Feedback

Navigating the complexities of pharmaceutical regulatory compliance requires a deep understanding of international guidelines. Welcome to "Evaluating ICH Q3B(R2) Reporting Thresholds for Degradation Products," a specialized course designed for pharmaceutical professionals, quality assurance experts, and regulatory affairs specialists.

Navigating the complexities of pharmaceutical regulatory compliance requires a deep understanding of international guidelines. Welcome to "Evaluating ICH Q3B(R2) Reporting Thresholds for Degradation Products," a specialized course designed for pharmaceutical professionals, quality assurance experts, and regulatory affairs specialists. This comprehensive training program demystifies the ICH Q3B(R2) guideline, focusing specifically on the reporting thresholds for degradation products in chemically synthesized new drug products.

Throughout this course, you will explore the critical scope of the ICH Q3B(R2) guideline, learning exactly which product categories are covered and which are excluded, such as biologics, peptides, and oligonucleotides. We will dive deep into the two primary reporting-threshold values—0.1% for a maximum daily dose of ≤ 1 g, and 0.05% for a maximum daily dose > 1 g—and the scientific rationale behind how these thresholds scale with patient ingestion.

Beyond theoretical knowledge, this course emphasizes practical application and operational rules. You will learn how to execute the correct reporting workflow, identify common industry errors (like defaulting to 0.1% regardless of dose), and differentiate compliant from non-compliant practices to mitigate data-integrity risks. Featuring real-world case studies and a robust 10-Point Audit/Inspection-Readiness Checklist, this course ensures you are fully equipped to make defensible, risk-based decisions. Enroll today to safeguard patient safety, ensure product quality, and maintain impeccable regulatory compliance in your degradation reporting processes.

116. Evaluating ICH Q3B(R2) Reporting Thresholds for Degradation Products

<div class="simple-box-wrapper">
    <div class="simple-box">
        <div class="column">
            <p>Ensuring the safety and efficacy of chemically synthesized new drug products requires rigorous monitoring of degradation products throughout their shelf life. The International Council for Harmonisation (ICH) Q3B(R2) guideline establishes a standardized framework for identifying, qualifying, and reporting these impurities. For quality control analysts, quality assurance reviewers, and regulatory affairs professionals, mastering these reporting thresholds is not merely a compliance exercise; it is a fundamental component of safeguarding patient health and maintaining data integrity. Accurate evaluation of degradation products directly impacts batch release decisions, stability assessments, and the successful drafting of regulatory dossiers.</p>

<p>This course provides a comprehensive examination of the ICH Q3B(R2) reporting thresholds, specifically focusing on how these limits scale with the maximum daily dose of a drug product. Participants will explore the precise scope of the guideline, distinguishing covered products from excluded categories such as biologics, peptides, oligonucleotides, and leachables. Through detailed analysis of operational rules and real-world case studies, the curriculum addresses critical workflows, common reporting errors, and borderline scenarios that require defensible, risk-based decision-making. Furthermore, an inspection-readiness checklist will equip analytical scientists and stability coordinators with the necessary controls to ensure method quantitation limits align with regulatory expectations, thereby fortifying the integrity of analytical reporting and continuous process improvement.</p>
        </div>
    </div>
</div>
